Advertisement
AVIR vs AXON
Which Stock Would AI Choose? Atea Pharmaceuticals (AVIR) vs. Axon Enterprise (AXON) Stock Comparison
Key Takeaways
- AVIR is a clinical-stage biopharmaceutical company with no current product revenue, while AXON is a profitable, fast-growing public safety technology leader.
- AVIR's recent Phase 3 hepatitis C data met its primary endpoint, but commercialization and further trial readouts remain key catalysts.
- AXON has posted revenue growth of roughly 34–35% in recent quarters, yet its shares have declined substantially from prior highs on valuation and sector concerns.
- The two companies differ sharply in market positioning, risk profile, and growth drivers, making this an instructive contrast across sectors.
- AVIR offers higher potential upside with binary clinical risk, while AXON offers established cash flow and momentum with premium valuation sensitivity.
Introduction
Comparing AVIR and AXON is less about picking a single "winner" than about understanding two very different investment profiles. Atea Pharmaceuticals is an early-stage antiviral drug developer whose value hinges on clinical trial outcomes, whereas Axon Enterprise is an established public safety technology company generating substantial recurring revenue. This stock comparison is relevant for investors weighing high-risk, catalyst-driven biotechnology against a growth-oriented hardware-and-software business with proven earnings. By examining relative performance, market positioning, and sentiment, traders and long-term investors can better assess where each name fits within a diversified approach.
AVIR Overview and Recent Performance
AVIR (Atea Pharmaceuticals) is a clinical-stage biopharmaceutical company focused on oral antiviral therapies for serious viral infections, including hepatitis C virus (HCV), hepatitis E virus (HEV), and dengue. Because the company has not yet commercialized a product, its financial results primarily reflect research and development (R&D) spending rather than revenue.
Recent weeks have been shaped by clinical milestones. Atea reported positive topline results from its Phase 3 C-BEYOND trial, in which its bemnifosbuvir and ruzasvir combination met its primary endpoint of statistical non-inferiority versus the standard-of-care regimen for chronic HCV. The company also completed enrollment in its second Phase 3 study, C-FORWARD, with more than 880 patients across 17 countries. Management has indicated a cash runway extending through 2027, which reduces near-term financing pressure but leaves the equity sensitive to trial outcomes. Sentiment has been generally constructive, with analysts citing a consensus "Buy" rating and price targets above recent trading levels, though the stock's relative performance remains volatile given the binary nature of biotech catalysts.
AXON Overview and Recent Performance
AXON (Axon Enterprise) is a global leader in public safety technology, offering TASER energy devices, body-worn and in-car cameras, drones and counter-drone systems, digital evidence management, and AI-driven software. Its integrated ecosystem spans law enforcement, enterprise security, and national security customers.
Recent market activity reflects a tension between strong fundamentals and valuation concerns. Axon reported revenue of approximately $807 million in its first quarter and roughly $904 million in its second quarter, representing year-over-year growth of about 34–35%, and raised its full-year revenue growth outlook. Growth has been broad-based, led by software and services, the AI Era Plan, and counter-drone solutions such as Dedrone. Despite this momentum, the stock has declined meaningfully from its 52-week high and remains well below prior peaks, as investors weigh a premium valuation multiple against broader sector compression and rising competition. The company also raised capital through convertible notes in recent weeks, a development some investors interpret as both a growth signal and a potential dilution consideration.
Trending AI Robots
For traders seeking a systematic edge across names like these, Tickeron's Trending AI Robots page curates a focused selection of AI-powered trading bots. Tickeron operates hundreds of AI trading bots that monitor thousands of different tickers, but only those best suited to current market conditions earn a place in this curated section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they trade, giving users a range of approaches to explore. Whether you are evaluating momentum-driven setups or volatility-sensitive strategies, the Trending AI Robots section offers a practical way to review data-driven signals that adapt to shifting markets.
Head-to-Head Comparison
The core contrast between AVIR and AXON lies in business model maturity. AVIR is pre-revenue and depends on regulatory approvals and eventual commercialization of antiviral therapies; its risk is concentrated in clinical outcomes and funding. AXON, by contrast, generates substantial recurring revenue across hardware and software subscriptions, with a diversified product roadmap spanning drones, AI, and counter-drone systems.
Growth drivers also differ. AVIR's upside is tied to discrete catalysts such as upcoming Phase 3 readouts and potential new drug applications (NDAs), which can produce sharp, discontinuous price moves. AXON's growth is more secular and recurring, driven by expanding public safety budgets, AI adoption, and cross-selling across its ecosystem, though its valuation and margin pressures from tariffs and competition introduce their own risks.
On market positioning, AVIR operates in a competitive antiviral landscape dominated by large pharmaceutical incumbents, while AXON holds a leading position in a specialized public safety niche. Sentiment toward AVIR has been lifted by positive trial data, whereas sentiment toward AXON has been mixed despite strong results, reflecting valuation sensitivity. In short, AVIR offers higher-beta, catalyst-dependent exposure, while AXON offers established growth with execution and valuation risk.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor AXON in the current environment, primarily because of its trend consistency and fundamental stability. Axon has demonstrated sustained revenue growth, raised guidance, and maintained a strong recurring-revenue profile, which tends to produce more stable and persistent price trends than a pre-revenue biotech. AVIR, while benefiting from positive clinical momentum, carries binary risk around future trial readouts and regulatory milestones that can generate abrupt reversals. This does not imply AVIR lacks opportunity—its catalysts could drive significant moves—but from a probabilistic, trend-oriented standpoint, AXON's steadier positioning and clearer earnings trajectory appear more aligned with conditions that AI models typically reward. The assessment remains probabilistic and subject to change as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Buy and AXON is a StrongBuy.
AVIR in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 13, 2026
AVIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 33 cases where AVIR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AVIR's RSI Oscillator exited the oversold zone, 24 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 36 of 54 cases where AVIR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on AVIR as a result. In 67 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for AVIR just turned positive on November 03, 2026. Looking at past instances where AVIR's MACD turned positive, the stock continued to rise in 29 of 40 cases over the following month. The odds of a continued upward trend are 73%.
Following a +4.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVIR advanced for three days, in 197 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day moving average for AVIR crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
The 50-day moving average for AVIR moved below the 200-day moving average on November 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for AVIR entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.693) is normal, around the industry mean (3.498). P/E Ratio (-2.072) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. AVIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AXON's RSI Oscillator is sitting in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 55 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 31 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
AVIR | AXON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 83 | |
SMR RATING 1..100 | 98 | 81 | |
PRICE GROWTH RATING 1..100 | 61 | 65 | |
P/E GROWTH RATING 1..100 | 33 | 80 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AVIR's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for AXON (90). This means that AVIR’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as AVIR (100). This means that AXON’s stock grew similarly to AVIR’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as AVIR (98). This means that AXON’s stock grew similarly to AVIR’s over the last 12 months.
AVIR's Price Growth Rating (61) in the Biotechnology industry is in the same range as AXON (65). This means that AVIR’s stock grew similarly to AXON’s over the last 12 months.
AVIR's P/E Growth Rating (33) in the Biotechnology industry is somewhat better than the same rating for AXON (80). This means that AVIR’s stock grew somewhat faster than AXON’s over the last 12 months.
| AVIR | AXON | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 67% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 72% | 1 day ago 73% |
| MACD ODDS (%) | 1 day ago 73% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 69% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 71% |
| Advances ODDS (%) | 1 day ago 76% | 14 days ago 74% |
| Declines ODDS (%) | 8 days ago 77% | 1 day ago 70% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AVIR’s FA Score shows that 1 FA rating(s) are green while AXON’s FA Score has 0 green FA rating(s).
- AVIR’s FA Score: 1 green, 4 red.
- AXON’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AVIR’s TA Score shows that 6 TA indicator(s) are bullish while AXON’s TA Score has 4 bullish TA indicator(s).
- AVIR’s TA Score: 6 bullish, 4 bearish.
- AXON’s TA Score: 4 bullish, 4 bearish.
Price Growth
AVIR (@Biotechnology) experienced а +7.56% price change this week, while AXON (@Aerospace & Defense) price change was -28.74% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.23%. For the same industry, the average monthly price growth was -8.97%, and the average quarterly price growth was +85.13%.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +2.83%. For the same industry, the average monthly price growth was -3.84%, and the average quarterly price growth was -16.10%.
Reported Earning Dates
AVIR is expected to report earnings on Mar 02, 2027.
AXON is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (+2.23% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Aerospace & Defense (+2.83% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
Advertisement
AVIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To AVIR | 1D Price Change % | ||
|---|---|---|---|---|
| AVIR | 100% | +2.32% | ||
| AXON - AVIR | 46% Loosely correlated | -3.14% | ||
| ANRO - AVIR | 38% Loosely correlated | +10.49% | ||
| KRRO - AVIR | 37% Loosely correlated | +1.42% | ||
| NKTX - AVIR | 36% Loosely correlated | -8.09% | ||
| VCYT - AVIR | 36% Loosely correlated | +7.28% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HBMX | 18.02 | 1.33 | +7.97% |
| Tuttle Capital Concentrated Memory Stack ETF (HBMX) | |||
| WDTE | 27.19 | 0.58 | +2.18% |
| Defiance S&P 500 Weekly Distribution ETF (WDTE) | |||
| LGI | 16.75 | 0.25 | +1.52% |
| Lazard Global Total Return & Income Fund | |||
| AVRE | 47.48 | 0.67 | +1.43% |
| Avantis Real Estate ETF (AVRE) | |||
| IUSB | 44.97 | 0.03 | +0.07% |
| iShares Core Total USD Bond Market ETF (IUSB) | |||